Revolution Medicines, Inc. (RVMD) Balance Sheet

The balance sheet has expanded dramatically, with total assets more than doubling over the period, primarily due to a substantial equity infusion in 2026Q2. However, retained earnings have deteriorated from -$1.3B to -$4.0B, reflecting the accelerating R&D burn. This suggests the company is in a heavy investment phase, but the widening losses raise questions about the sustainability of this trajectory without continued capital access.

The debt-to-equity ratio has climbed from 0.05 to 0.25, with total debt jumping to $641.9M, likely reflecting a convertible or term loan facility. While leverage remains modest relative to equity, the rapid increase suggests the company is diversifying funding sources beyond equity. Investors should monitor refinancing risk, especially given the lack of revenue to service debt, though the current low D/E provides some cushion.

The asset base is dominated by cash and investments, with PP&E representing a small but growing share, up 63% over the period. Goodwill is negligible, suggesting no major acquisitions. This mix underscores a business model that relies on human capital and outsourced manufacturing rather than heavy fixed assets, which may limit collateral but also reduces depreciation drag.

The equity base has been bolstered by significant capital raises, but the accumulated deficit continues to widen, and SBC is a major non-cash charge. This suggests that reported equity overstates the company's intrinsic value, as a large portion is funded by investor capital rather than operational success. Shareholders should be aware of potential dilution from future equity offerings.

While the current ratio remains high at 11.38, the absolute cash position of $815.4M is only slightly above the quarterly operating cash outflow of $741.5M, implying a cash runway of just over one quarter without additional financing. This indicates a precarious liquidity position despite the healthy ratio, as the company's burn rate has escalated sharply.